Cargando…

Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data

OBJECTIVE: To describe the real-world use of adalimumab for maintenance treatment of ulcerative colitis (UC) and associated healthcare costs in English hospitals. DESIGN: Retrospective cohort study. SETTING: Analysis of NHS Hospital Episode Statistics linked with pharmacy dispensing data in English...

Descripción completa

Detalles Bibliográficos
Autores principales:	Black, Christopher M., Yu, Eric, McCann, Eilish, Kachroo, Sumesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768958/ https://www.ncbi.nlm.nih.gov/pubmed/26919745 http://dx.doi.org/10.1371/journal.pone.0149692

Ejemplares similares

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study
por: Sebastian, Shaji, et al.
Publicado: (2019)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany
por: Sullivan, Emma, et al.
Publicado: (2017)

Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
por: Singh, Harpreet, et al.
Publicado: (2023)

Long-term outcomes of colectomy surgery among patients with ulcerative colitis
por: Brown, Carl, et al.
Publicado: (2015)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
por: Beilman, Candace L., et al.
Publicado: (2016)

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study
por: Bessissow, Talat, et al.
Publicado: (2022)

Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2020)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013)

Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection
por: Lee, Jin-Hyup, et al.
Publicado: (2017)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
por: Wessman, Laurel L., et al.
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Kim, Jae Hyun, et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
por: Hoffmann, Sebastian, et al.
Publicado: (2018)

Reversible Corpus Callosal Lesions Associated with the Use of Adalimumab for Ulcerative Colitis
por: Park, Jin-Woo, et al.
Publicado: (2017)

Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review
por: Luttropp, Karin, et al.
Publicado: (2019)

Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
por: Long, Millie D., et al.
Publicado: (2022)

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis
por: Wagner, Frank, et al.
Publicado: (2023)

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
por: Svedbom, Axel, et al.
Publicado: (2017)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Okabayashi, Shinji, et al.
Publicado: (2017)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab
por: Alshehri, Hamza, et al.
Publicado: (2023)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study
por: Dalén, Johan, et al.
Publicado: (2020)

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
por: Chandra, Alok, et al.
Publicado: (2019)

Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis
por: Rispo, Antonio, et al.
Publicado: (2016)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring
por: Wasserbauer, Martin, et al.
Publicado: (2022)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation
por: Politis, Dimitrios S., et al.
Publicado: (2019)

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease
por: Dubinsky, Marla C., et al.
Publicado: (2016)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hpg6t32mdp1hcnq6mtak16csnf